In-vitro diagnostics and laboratory services company Renalytix plc (NASDAQ:RNLX) (LSE:RENX) announced on Friday Medicare's final coverage determination for its kidney disease test, kidneyintelX.dkd.
The test is approved for patients with type 2 diabetes and early-stage chronic kidney disease, with coverage starting 1 August 2024. The established Medicare price for kidneyintelX.dkd is USD950 per test.
This decision follows FDA authorisation, clinical data, guideline inclusion and broad insurance coverage, paving the way for wider test adoption.
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Lupin launches Dasatinib tablets in US market
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA
FDA approves Tenpoint Therapeutics' YUVEZZI as first dual-agent eye drop for presbyopia
Summit Therapeutics' BLA for ivonescimab in EGFR-mutated NSCLC accepted by FDA
WuXi Biologics collaborates with Sinorda Biomedicine for antibody development
Biogen's litifilimab receives FDA Breakthrough Therapy Designation for CLE
Glaukos receives FDA approval for repeat administration of iDose TR
Guerbet's contrast agent Elucirem approved by European Commission in children from birth
Spine Innovation's LOGIC Titanium Implant System receives US FDA 510(k) market approval